文献速递临床试验与 GCP真实世界研究与卫生经济

卡塔尔糖尿病移动应用试验(QDMAT):一项开放标签随机对照试验,旨在检验使用移动应用改善2型糖尿病糖尿病照护的效果——研究方案

Qatar Diabetes Mobile Application Trial (QDMAT): an open-label randomised controlled trial to examine the impact of using a mobile application to improve diabetes care in type 2 diabetes mellitus-a study protocol.
PubMed 文献 · Trials · 2022-06-16

该研究方案为一项正在进行的开放标签随机对照试验,计划纳入180例接受胰岛素治疗的成人2型糖尿病患者,按1:1随机分配至使用糖尿病移动应用组或当前标准照护组。主要结局为基线至6个月的平均HbA1c差异,其他结局包括人体测量指标、低血糖事件、药物调整、临床互动次数、错过预约及患者对疾病和糖尿病自我管理的感知。研究假设该糖尿病专用移动应用将改善血糖控制、增强患者自我管理能力并改善医患互动。

要点

  • 方案为开放标签随机对照试验,计划随机180例接受胰岛素治疗的成人2型糖尿病患者。
  • 主要结局为基线至6个月的平均HbA1c差异,比较移动应用组与当前标准照护组。
  • 研究假设该糖尿病专用移动应用将改善血糖控制、增强患者自我管理能力并改善医患互动。

核心结论

  • 研究假设该糖尿病专用移动应用将改善血糖控制、增强患者自我管理能力并改善医患互动。
  • 若QDMAT试验证明该移动应用有效,将为未来2型糖尿病自我管理的临床服务提供依据。

研究设计与样本

  • 正在进行的开放标签随机对照试验,将接受胰岛素治疗的成人2型糖尿病患者按1:1随机分配至使用糖尿病移动应用组或当前标准照护组。
  • 计划随机180例受试者用于主要结局评估。
  • 主要结局为基线至6个月的平均HbA1c差异。
  • 其他结局包括人体测量指标、低血糖事件、药物调整、临床互动次数、错过预约及患者对疾病和糖尿病自我管理的感知。
  • 试验注册号:ClinicalTrials.gov NCT03998267,注册日期2019年6月26日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mobile health (mHealth) is increasingly advocated for diabetes management. It is unclear if mobile applications are effective in improving glycaemic control, clinical outcomes, quality of life and overall patient satisfaction in patients with type 2 diabetes (T2DM). A new mobile application was specifically built for people with T2DM with the help of the local expertise. The objective of the study was to evaluate the effectiveness of the mobile app. METHODS: The planned study is an ongoing open-label randomised controlled trial in which adults living with T2DM treated with insulin will be randomised 1:1 to the use of this diabetes application versus current standard care. The primary outcome will be the difference in mean HbA1c from baseline to 6 months. Other outcome measures include anthropometric measures, hypoglycaemic events, medication adjustments, number of clinical interactions and missed appointments and patient perceptions of their disease and diabetes self-management. The study will randomise 180 subjects for assessment of the primary outcome. DISCUSSION: We hypothesise that the diabetes-specific mobile application will improve glycaemic control, increase patient empowerment for self-management of diabetes and improve interaction between patients and healthcare providers. If the Qatar Diabetes Mobile Application Trial (QDMAT) demonstrates this, it will inform clinical services for the future self-management of T2DM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03998267 . Registered on 26 June 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Suleiman N, Alkasem M, Al Amer Z, et al. Qatar Diabetes Mobile Application Trial (QDMAT): an open-label randomised controlled trial to examine the impact of using a mobile application to improve diabetes care in type 2 diabetes mellitus-a study protocol. Trials. 2022. PMID: 35710428. doi:10.1186/s13063-022-06334-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。